YC-1: A Soluble Guanylyl Cyclase Activator and HIF-1α Inhibitor for Advanced Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule and potent soluble guanylyl cyclase (sGC) activator, supplied by APExBIO (B7641). YC-1 selectively inhibits hypoxia-inducible factor-1α (HIF-1α) transcriptional activity with an IC50 of 1.2 µM under hypoxic conditions. In vitro, YC-1 inhibits platelet aggregation and vascular contraction via sGC activation, while in vivo studies show reduced tumor growth and vascularization. The compound is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but insoluble in water, and is typically ≥98% pure. YC-1 is an essential tool for dissecting the hypoxia signaling pathway and cGMP signaling in cancer biology research (APExBIO).

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a master transcription factor that regulates the expression of genes involved in cellular adaptation to low oxygen, including those governing angiogenesis, apoptosis, and tumor metabolism (APExBIO). Under hypoxic conditions, HIF-1α accumulates, translocates to the nucleus, and activates the transcription of genes that facilitate tumor survival, invasion, and metastasis. The oxygen-sensing pathway, which includes HIF-1α, is a critical driver of tumor progression in solid cancers. Inhibiting HIF-1α disrupts hypoxia-mediated transcription and suppresses tumor growth and vascularization. Soluble guanylyl cyclase (sGC) is another key signaling protein regulated by nitric oxide (NO), mediating vasodilation, platelet inhibition, and smooth muscle relaxation via cyclic guanosine monophosphate (cGMP) generation (Elama et al., 2022). YC-1 interacts with both pathways, enabling precise control over hypoxia and cGMP signaling in research models.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 was originally characterized as a direct sGC activator, increasing cGMP production independently of NO (Elama et al., 2022). This effect leads to inhibition of platelet aggregation and vascular smooth muscle contraction. Separately, YC-1 acts as a post-transcriptional inhibitor of HIF-1α. It destabilizes HIF-1α protein, reducing its nuclear accumulation and subsequent transcriptional activation of hypoxia-responsive genes. In tumor models, YC-1 treatment leads to reduced HIF-1α protein levels and downregulation of VEGF and other angiogenic factors. The dual-action mechanism—sGC activation and HIF-1α inhibition—enables YC-1 to modulate both vascular and hypoxic responses in a context-dependent manner.

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC50 of 1.2 µM in vitro (standard cell culture, 1% O₂, 24 h) (APExBIO).
• In rodent xenograft tumor models, YC-1 administration (10 mg/kg, i.p., daily, 14 days) resulted in smaller, less vascularized tumors and decreased HIF-1α/VEGF expression (see review for translational context).
• YC-1 activates sGC, increasing cGMP levels and inhibiting platelet aggregation ex vivo at concentrations ≥1 µM (Elama et al., 2022).
• The compound is soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but not in water; purity is typically ≥98% (APExBIO).
• YC-1 does not inhibit PDE5, distinguishing it from vardenafil and sildenafil, which act via PDE5 inhibition in the cGMP pathway (Elama et al., 2022).

Applications, Limits & Misconceptions

YC-1 is widely used for:

• Dissecting hypoxia signaling pathways and tumor microenvironment mechanisms (Compare: Optimizing Hypoxia and Cytotoxicity Assays; this article provides product-specific solubility and benchmark details not covered in prior method-focused reviews).
• Modeling tumor angiogenesis inhibition and apoptosis in vitro and in vivo (Contrast: Leveraging YC-1 for Dual Mechanism Studies; here, the emphasis is on validated dosing and purity for reproducibility).
• Studying vascular tone modulation via the cGMP signaling pathway.

YC-1 is not intended for diagnostic or therapeutic use in humans. It does not function as a PDE5 inhibitor, and cannot substitute for vardenafil, sildenafil, or tadalafil in erectile dysfunction or LUTS clinical settings (Elama et al., 2022).

Common Pitfalls or Misconceptions

• YC-1 is not bioavailable orally and is unsuitable for systemic administration in humans.
• It does not directly inhibit phosphodiesterase 5 (PDE5).
• YC-1's effects are context-dependent; hypoxia-independent pathways may not respond.
• Long-term solutions in DMSO or ethanol are unstable; prepare fresh for each experiment (APExBIO).
• Do not store dissolved YC-1 at 4°C for extended periods; precipitate or degradation may occur.

Workflow Integration & Parameters

For in vitro studies, dissolve YC-1 in DMSO or ethanol at concentrations up to 30.4 mg/mL and 16.2 mg/mL, respectively. Typical working concentrations range from 0.1–10 µM. For in vivo models, intraperitoneal injection is recommended, as the compound is not water soluble. Solutions should be freshly prepared prior to use, and protected from light. Use validated antibodies and controls for HIF-1α detection. For cytotoxicity, proliferation, or angiogenesis assays, include matched vehicle controls. For hypoxia modeling, maintain oxygen tension at 1–2% O₂ during YC-1 exposure (see protocol article for scenario-driven guidance not detailed here).

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, as supplied by APExBIO, is a validated research tool for interrogating hypoxia signaling, tumor angiogenesis, and the cGMP pathway. Its dual mechanism of sGC activation and HIF-1α inhibition enables unique experimental designs in cancer and vascular biology. Ongoing research explores new applications in mitochondrial quality control and neuroprotection (see mechanistic insights article; this review extends mechanistic context with product-specific practicalities). Researchers should adhere to recommended storage and usage parameters to ensure reproducibility. The precise targeting capabilities of YC-1 make it a cornerstone in the molecular dissection of oxygen-sensing pathways in oncology and vascular research.